About Us

About Us

About Us Aligos is discovering and developing new classes of molecules that interact directly with disease-causing modalities such as viral encoded proteins and nucleic acids, as well as oncogenes and their resultant proteins in the case of our...
Company Mission

Company Mission

Curative Therapies Duis ligula libero lacinia Company Mission To become a world leader in the development of targeted, curative therapies for hepatologic diseases and viral infections including chronic hepatitis B (CHB), non-alcoholic steatohepatitis...
Contact

Contact

Aligos’ Locations US Office European Office 1 Corporate Dr., 2nd Floor San Francisco, CA 94080 info@aligos.com Gaston Geenslaan 1 / (building 3) 3001 Leuven, Belgium info@aligos.com Google...

Home

Our Mission Aligo aims to become a world leader in the development of targeted, curative treatments for hepatologic diseases and viral infections, including chronic hepatitis B (CHB), nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma...
Investors

Investors

Working out of Copenhagen, with affiliates in San Francisco and Boston, Novo Holdings is a world-leading life science investor with a focus on creating long-term value. The Roche Venture Fund invests in early stage biotech, digital...
Management Team

Management Team

Management Team Board of Directors Management Team Lawrence Blatt, Ph.D., MBA Chief Executive Officer Global Infectious Diseases Therapeutic Area Head – Janssen Co-Founder, Chief Executive Officer – Alios BioPharma C...
Partners

Partners

In June 2018, Aligos entered into an agreement with Emory University whereby Aligos acquired from Emory an exclusive license to technology with respect to a novel class of non-nucleoside class-II capsid assembly modulators. The underlying technology...
Platform & Pipeline

Platform & Pipeline

With Aligos’ extensive expertise and experience in developing therapeutics for chronic liver diseases, we are building a robust pipeline of best-in-class drug candidates focused on developing curative therapies for chronic Hepatitis B and delivering transformative treatments in other areas of liver disease. Development Pipeline Aligos Therapeutics (Aligos) is targeting multiple, clinically validated mechanisms of action (MOAs) as it seeks to identify curative therapies for hepatologic diseases and viral infections, including chronic hepatitis B (CHB), nonalcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC). Aligos’ development program MOAs include: Capsid assembly modulators (CAMs)*: : Also known as hepatitis B virus (HBV) core inhibitors, CAMs are small molecule allosteric inhibitors that interfere with the formation of intact (i.e., infectious) HBV particles. In the presence of CAMs, non-infectious empty (Class II CAMs) or aberrantly shaped (Class I CAMs) viral particles are produced instead. In CHB clinical trials, treatment with Class II CAMs has resulted in significant reductions in HBV nucleic acids (deoxyribonucleic acids (DNA) and ribonucleic acids (RNA)) (1, 2). Aligos has identified multiple promising Class II and Class I CAMs, that are currently being optimized. Aligos’ most advanced CAM, ALG-000184, has best in class properties compared to other Class II CAMs currently in development and is due to enter the clinic in 2020.   S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPS)* : STOPS (closely related to nucleic acid Polymers (NAPs)) are oligonucleotides that work via an as yet undefined mechanism of action that results in profound inhibition of Hepatitis B surface antigen (HBsAg) formation in vitro and in CHB clinical trials (3). HBsAg is thought to have broad Immunosuppressive properties in CHB patients, preventing eradication of the virus (4). As a result, sustained HBsAg loss is considered an essential step to achieving functional cure of CHB (5). Aligos’ lead STOP candidate, ALG-010133, appears to have best in class properties compared to other STOPS currently in development and is due to enter the clinic in 2020.   Antisense oligonucleotides (ASOs)* : ASOs are oligonucleotides that bind to complementary messenger RNAs (mRNAs) and trigger their degradation via the enzyme Ribonuclease H (RNAse H). ASOs can therefore be used to target viral mRNAs such as those encoding the HBsAg protein to lower HBsAg levels and enable reconstitution of the host immune system against the virus. Aligos has a number of ASOs in development that may offer best-in-class properties compared to other oligonucleotide approaches currently in the clinic.   Thyroid hormone receptor beta (THR-β) agonists :Thyroid hormone receptors (THRs) are composed of two main sub-classes (alpha and beta) that are stimulated by the thyroid hormone, triiodothyronine (T3). Over stimulation of THR alpha results in tachycardia, bone loss, and muscle wasting, while THR beta stimulation primarily affects the liver and results in reductions in lipids, including cholesterol, triglycerides, and liver fats (steatosis). Therefore, selective stimulation of THR-β receptors has the potential to reduce a patient’s lipid burden, including the steatosis which underpins NASH, while avoiding unwanted THR alpha-mediated side effects. Indeed, several THR-β agonists are in the clinic and have demonstrated favorable effects on plasma lipid levels, liver fat burden, as well as liver histology (6, 7) in NASH patients. Aligos has THR-β agonists in development that may offer best-in-class properties compared to other compounds currently in the clinic.   Aligos is currently optimizing and validating a number of compounds targeting undisclosed MOAs which are thought to be central to the pathogenesis of HCC.  
Presentation

Presentation

Presentation J.P. Morgan Healthcare Conference January 14th, 2020 Download Audio Download Presentation
Press & Publications

Press & Publications

Sed in bibendum velit. Suspendisse ullamcorper sapien orci San Joe, June 21, 2018 – Donec gravida dui et sagittis elementum. Sed in bibendum velit. Suspendisse ullamcorper sapien orci, tempus luctus magna lobortis sed. Sed orci erat, euismod vel d...

Privacy Policy

Privacy Policy Who we are Our website address is: http://localhost/aligos. What personal data we collect and why we collect it Comments When visitors leave comments on the site we collect the data shown in the comments form, and also the visitor’s I...